These glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have both extended half-lives while maintaining potency which has resulted in an effective treatment of Type-2 Diabetes
The studies demonstrated substantial weight reduction, along with significant improvements in several obesity-associated comorbidities, including knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea (OSA), and type 2 diabetes
In vitro evaluation
Todays prescription weight loss medications include both oral weight loss pills and injectable therapies
NLY01, a novel GLP1 analogue, demonstrates unforeseen disease modification potential in multiple Parkinson models through blocking microglial activation and preventing A1 astrocyte induction
Yucca uses licensed providers in all 50 states, US-licensed pharmacies, and US-based expedited shipment, which directly addresses some of the most common trust concerns patients raise about smaller telehealth brands